Estimates of finasteride-induced gynecomastia (FIG) prevalence vary widely, ranging from 1% to 6% in clinical trials, potentially higher in post-marketing surveillance. This discrepancy highlights challenges in accurately identifying and reporting FIG cases.
Age and Genetic Predisposition
Age plays a significant role; younger men seem more susceptible. A genetic predisposition to hormonal imbalances may also increase risk, although specific genes haven’t been definitively identified. Family history of gynecomastia should prompt caution.
Concurrent Medications and Underlying Conditions
Several medications, such as ketoconazole and spironolactone, can interact with finasteride, increasing FIG risk. Pre-existing liver or kidney disease may further elevate the chance of developing this side effect. Careful medical history review is crucial.
Dosage and Duration of Treatment
Higher doses and prolonged finasteride use correlate with increased FIG risk. Individual responses vary; however, minimizing both dose and duration is sensible when possible.
Table 1: Summary of Risk Factors
| Younger Age | Increased hormonal sensitivity |
| Genetic Predisposition | Family history of gynecomastia |
| Concurrent Medications | Interactions with other drugs |
| Underlying Health Conditions | Liver or kidney disease |
| Higher Dose/Longer Duration | Increased exposure to finasteride |
Lifestyle Factors
While evidence is limited, some suggest certain lifestyle factors might play a minor role. Obesity and unhealthy diets, for example, could indirectly influence hormone balance.
